SCHEMBL10242915

SCHEMBL10242915

CCCNC(=O)Cc1cccc(-c2ccco2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.53
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49
KEAP1 Q14145 1/20 0.46
POLB P06746 3/20 0.44
HIF1A Q16665 1/20 0.44
PSMB5 P28074 3/20 0.44
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
PTPN7 P35236 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TRPV1 Q8NER1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242902 0.93 PRMT6 (0.51) PRMT6ALDH1A1HPGDGAAKEAP1
SCHEMBL10242931 0.90 PRMT6 (0.56) PRMT6ALDH1A1HPGDSMN1; SMN2KEAP1
SCHEMBL12303899 0.88 PRMT6 (0.51) PRMT6ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL10242926 0.85 ALDH1A1 (0.49) ALDH1A1HPGDSMN1; SMN2NPC1LMNA
SCHEMBL10242917 0.84 ALDH1A1 (0.49) PRMT6ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL12250924 0.84 PRMT6 (0.52) PRMT6ALDH1A1HPGDSMN1; SMN2KEAP1
SCHEMBL1927063 0.81 TRPV1 (0.53) ALDH1A1HPGDSMN1; SMN2LMNAGAA
SCHEMBL10242930 0.80 PRMT6 (0.60) PRMT6ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL10242978 0.79 KEAP1 (0.58) PRMT6ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL5662919 0.79 PRMT6 (0.58) PRMT6ALDH1A1HPGDSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885ALDH1A1 1939/4885HPGD 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.